Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | MME | P08473 | 3/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | TMPRSS15 | P98073 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600767 | 1.00 | CA2 (0.48) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL29084669 | 0.98 | CA2 (0.47) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL29238518 | 0.83 | TGFBR1 (0.39) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL163120 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL30300609 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL163119 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL5493514 | 0.82 | CA2 (0.52) | CA2CA4CA1MMETGFBR1 | |
| SCHEMBL12205353 | 0.81 | CA2 (0.49) | CA2CA4CA1MMEPRSS1 | |
| SCHEMBL14592685 | 0.81 | CA2 (0.47) | CA2CA4CA1MMEPRSS1 | |
| SCHEMBL28241652 | 0.80 | TGFBR1 (0.40) | CA2CA4CA1TGFBR1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024243687-A9 | METHODS OF SELECTING PREBIOTICS OPTIMIZED FOR AN INDIVIDUAL WITH INFLAMMATORY BOWEL DISEASE | UNIVERSITY OF OTTAWA (CA) | 2025-06-19 | — | — | WO | disclosed |
| US-20250138016-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| WO-2024243687-A1 | METHODS OF SELECTING PREBIOTICS OPTIMIZED FOR AN INDIVIDUAL WITH INFLAMMATORY BOWEL DISEASE | UNIVERSITY OF OTTAWA (CA) | 2024-12-05 | — | — | WO | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | MALLE GERARD | 2009-08-06 | — | — | US | disclosed |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | L'OREAL S.A. | 2009-06-04 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | KRT18, INMT, INHA | CA2 1106/4885CA4 1779/4885CA1 3081/4885 |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | KRT18, KIT, PRDM7 | CA2 3522/4885CA4 2477/4885CA1 3572/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | CA2 3761/4885CA4 2728/4885CA1 3665/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | CA2 1238/4885CA4 1689/4885CA1 2285/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CA2 2042/4885CA4 3576/4885CA1 3422/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | CA2 2731/4885CA4 2386/4885CA1 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.